Compare Hasbro, Inc. (HAS) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs Moderna, Inc. — how do they compare? Hasbro, Inc. trades at $93.2 (market cap $13.05B), while Moderna, Inc. trades at $215.2 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 6× Hasbro, Inc.'s market cap, and Hasbro, Inc. pays a 3.03% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and Moderna, Inc. for 59 Days on average.
| HAS | MRNA | |
|---|---|---|
Market Cap | $13.05B | $78.65B |
Volume | 1,207,655 | 37,373,437 |
Sector | Consumer Cyclical | Health |
52-Week High | $105.88 | $203.46 |
52-Week Low | $70.95 | $22.36 |
Typical Hold Time | 97 Days | 59 Days |
Enterprise Value | $15.24B | $74.80B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $90.75, down 0.31% on the day, with strong technical momentum showing bullish moving average signals and key support at $90. The company demonstrates robust profitability with 64.41% gross margins and has beaten earnings estimates for three consecutive quarters, though 2025 showed a net loss of $322.4 million. Analyst consensus remains positive with a $107.60 price target and no sell ratings among 33 analysts.
Outlook remains constructive with projected 2026 revenue growth to $5.0B and net income of $794M, supported by Magic: The Gathering's strong performance. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The stock offers 18.5% upside to consensus target with institutional ownership showing mixed positioning.
Moderna (MRNA) trades at $196.48, up 4.81% with strong technical momentum as it joins the Nasdaq-100 index. Despite recent earnings beats, the company faces fundamental challenges with revenue declining from $18.9B in 2022 to $1.92B in 2025 and negative net income margins exceeding -140%. The stock's 500% rally in 2026 has pushed valuations to elevated levels with P/S ratio of 35.08, creating divergence between technical strength and financial fundamentals.
While Nasdaq inclusion and cancer vaccine pipeline progress offer catalysts, Moderna faces significant execution risks amid declining COVID revenue and high valuation multiples. Analyst consensus remains cautious with only 28% buy ratings and $115.70 price target well below current levels, suggesting limited near-term upside despite technical bullish signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
